IMR Press / CEOG / Volume 42 / Issue 1 / DOI: 10.12891/ceog1703.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
The effect of maternal polycystic ovary morphology on first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency thickness
Show Less
1 Department of Obstetrics and Gynecology, School of Medicine, Canakkale Onsekiz Mart University, Canakkale
2 Department of Clinical Biochemistry, School of Medicine, Canakkale Onsekiz Mart University, Canakkale (Turkey)
Clin. Exp. Obstet. Gynecol. 2015, 42(1), 32–35;
Published: 10 February 2015
Objective: To evaluate the effect of maternal polycystic ovary (PCO) morphology on maternal serum free beta-human chorionic gonadotropin (β-hCG), pregnancy associated plasma protein A (PAPP-A), and nuchal translucency (NT) thickness in the first-trimester. Material and Methods: A total of 92 pregnant women in the first-trimester were included in the study. Of them, 57 had PCO morphology, and 35 women constituted the control group, with apparently normal ovaries. Maternal serum free β-hCG, PAPP-A, and NT thickness were measured and compared in all patients. Results: The multiples of median (MoM) levels of serum free β-hCG were significantly higher in the PCO morphology group compared to the normal ovary group (p = 0.024). However, the MoM levels of PAPP-A were similar in both groups (p = 0.947). No difference was found between the groups in terms of fasting glucose levels and NT measurements (p = 0.976 and 0.565, respectively). Conclusion: In pregnancies with maternal PCO morphology, the presence of higher maternal serum free β-hCG levels may require correction in the calculation of risks related to first-trimester screening for chromosomal abnormalities. Larger studies are needed to confirm our preliminary data.
Maternal serum screening test
Nuchal translucency measurement
Polycystic ovary syndrome
Pregnancy-associated plasma protein-A
Back to top